Expanding access to genetic testing for pancreatic cancer.
Nicolette Juliana RodriguezSapna SyngalPublished in: Familial cancer (2024)
Among individuals with pancreatic ductal adenocarcinoma (PDAC) 5-10% have a pathogenic germline variant (PGV) in a PDAC susceptibility gene. Guidelines recommend genetic testing among all individuals with PDAC. Additionally, at-risk relatives of PDAC patients benefit from their own genetic education, risk assessment, and testing. Multigene panel testing (MGPT) can identify individuals with inherited cancer risk who can benefit from early cancer surveillance and risk reduction strategies. This manuscript discusses various healthcare delivery models for MGPT including traditional in-person genetic counseling, novel integrated in-person infrastructures, telemedicine genetics care via telephone- or video-visits and direct-to-consumer testing. Barriers and facilitators to care on the individual, provider, and system level are also outlined including specific considerations for historically marginalized communities.
Keyphrases
- healthcare
- risk assessment
- genome wide
- quality improvement
- end stage renal disease
- copy number
- palliative care
- newly diagnosed
- ejection fraction
- chronic kidney disease
- public health
- primary care
- papillary thyroid
- dna methylation
- prognostic factors
- health information
- pain management
- clinical practice
- peritoneal dialysis
- squamous cell
- oxidative stress
- dna repair
- social media
- antiretroviral therapy
- human immunodeficiency virus
- genome wide identification
- hiv infected